Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.
August 15, 2022 09:00 ET
|
Radius Health Inc.
CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Patient Square Capital (“Patient Square”) announced today the completion of their acquisition of Radius...
Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium
July 07, 2022 18:30 ET
|
Radius Health Inc.
Urges stockholders to vote “FOR” Radius’ highly qualified, independent director nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE proxy card...
Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome
July 07, 2022 08:00 ET
|
Radius Health Inc.
Advances asset in the neuro-endocrine orphan disease spaceSCOUT-015 clinical trial currently has 9 activated US sites and patient screening commenced30+ global sites are planned for the seamless Phase...
Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital
June 23, 2022 09:15 ET
|
Radius Health Inc.
Transaction delivers immediate value and liquidity to Radius shareholdersResult of nine-month strategic review process by the Radius Board to maximize shareholder valuePotential per share value of...
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant
June 22, 2022 16:30 ET
|
Radius Health Inc.
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patientsPriority Review requested; if accepted, anticipate an 8-month FDA reviewPositive EMERALD study data...
Radius Health Expands Non-US Market Footprint for TYMLOS
June 08, 2022 08:00 ET
|
Radius Health Inc.
Globalization has been a key priority for the Company over the past two yearsThree additional market agreements now signed and executed:- Labatec Pharma SA: Switzerland, Middle East & North Africa...
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
June 06, 2022 09:00 ET
|
Radius Health Inc.
FLORENCE, Italy and BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced the...
Radius Files Definitive Proxy and Mails Letter to Stockholders
June 06, 2022 07:30 ET
|
Radius Health Inc.
Urges Stockholders to Vote “FOR” Radius’ Highly Qualified, Independent Director Nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE Proxy Card...
Radius Health Update on Abaloparatide Transdermal System
June 01, 2022 16:15 ET
|
Radius Health Inc.
Company ascertained regulatory clarity for possible forward progression of abalo-TDSAdditional and successful clinical trial would be required to advance towards an NDA filingNew timeline for earliest...
Radius Adds Industry Veterans Jennifer A. Jarrett and Susan Vissers Lisa to Board of Directors
May 20, 2022 09:00 ET
|
Radius Health Inc.
Further Expands Board’s Expertise and Gender Diversity Enhances Corporate Governance BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today...